{"DataElement":{"publicId":"6042211","version":"1","preferredName":"Gamma-hydroxy-1,N(2)-propanodeoxyguanosine Level Text","preferredDefinition":"The level of Gamma-hydroxy-1,N(2)-propanodeoxyguanosine in the biopsy.","longName":"&gamma;-OHPdG_LEV_TX","context":"DCP","contextVersion":"1","DataElementConcept":{"publicId":"6042206","version":"1","preferredName":"Gamma-hydroxy-1,N(2)-propanodeoxyguanosine Level","preferredDefinition":"A mutagenic and carcinogenic cyclic 1,N2-propanodeoxy (Pd) DNA adduct derived from the reaction of deoxyguanosine (dG) in DNA with the environmentally widely available or endogenously produced mutagenic and carcinogenic unsaturated aldehyde acrolein (Acr) that can potentially be used as a biomarker for exposure to Acr, the formation of certain forms of cancer and the presence of oxidative stress. The formation of gamma-hydroxy-1,N(2)-propanodeoxyguanosine (g-OH-PdG) damages DNA and stimulates the formation of tumors. Also, as Acr is formed due to oxidation of certain polyunsaturated fatty acids (PUFAs), mostly omega-3-PUFA, the lipid peroxidation-derived DNA adduct g-OH-PdG can potentially be used as a biomarker to assess the presence of oxidized PUFAs, the level of oxidative stress and the extent of oxidative DNA damage._A position on a scale measuring intensity, quality, or amount.","longName":"6042204v1.0:2177479v1.0","context":"DCP","contextVersion":"1","ObjectClass":{"publicId":"6042204","version":"1","preferredName":"Gamma-hydroxy-1,N(2)-propanodeoxyguanosine","preferredDefinition":"A mutagenic and carcinogenic cyclic 1,N2-propanodeoxy (Pd) DNA adduct derived from the reaction of deoxyguanosine (dG) in DNA with the environmentally widely available or endogenously produced mutagenic and carcinogenic unsaturated aldehyde acrolein (Acr) that can potentially be used as a biomarker for exposure to Acr, the formation of certain forms of cancer and the presence of oxidative stress. The formation of gamma-hydroxy-1,N(2)-propanodeoxyguanosine (g-OH-PdG) damages DNA and stimulates the formation of tumors. Also, as Acr is formed due to oxidation of certain polyunsaturated fatty acids (PUFAs), mostly omega-3-PUFA, the lipid peroxidation-derived DNA adduct g-OH-PdG can potentially be used as a biomarker to assess the presence of oxidized PUFAs, the level of oxidative stress and the extent of oxidative DNA damage.","longName":"C133745","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gamma-hydroxy-1,N(2)-propanodeoxyguanosine","conceptCode":"C133745","definition":"A mutagenic and carcinogenic cyclic 1,N2-propanodeoxy (Pd) DNA adduct derived from the reaction of deoxyguanosine (dG) in DNA with the environmentally widely available or endogenously produced mutagenic and carcinogenic unsaturated aldehyde acrolein (Acr) that can potentially be used as a biomarker for exposure to Acr, the formation of certain forms of cancer and the presence of oxidative stress. The formation of gamma-hydroxy-1,N(2)-propanodeoxyguanosine (g-OH-PdG) damages DNA and stimulates the formation of tumors. Also, as Acr is formed due to oxidation of certain polyunsaturated fatty acids (PUFAs), mostly omega-3-PUFA, the lipid peroxidation-derived DNA adduct g-OH-PdG can potentially be used as a biomarker to assess the presence of oxidized PUFAs, the level of oxidative stress and the extent of oxidative DNA damage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"602D5C48-B77C-028B-E053-F662850A9EAF","latestVersionIndicator":"Yes","beginDate":"2017-12-12","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-12-12","modifiedBy":"ONEDATA","dateModified":"2017-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177479","version":"1","preferredName":"Level","preferredDefinition":"Level; a position on a scale of intensity or amount or quality.","longName":"Level","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Level","conceptCode":"C25554","definition":"A position on a scale measuring intensity, quality, or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-5228-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"DCP:Division of Cancer Prevention","workflowStatus":"RELEASED","registrationStatus":"Application","id":"602D5C48-B78A-028B-E053-F662850A9EAF","latestVersionIndicator":"Yes","beginDate":"2017-12-12","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-12-12","modifiedBy":"ZHANGWE","dateModified":"2018-01-09","changeDescription":"12/12/2017 wz created for DCP SVAR.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5811381","version":"1","preferredName":"Description Text","preferredDefinition":"A written or verbal account, representation, statement, or explanation of something._The words of something written.","longName":"5811381v1.0","context":"PBTC","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"250","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2208096","version":"1","preferredName":"Description  Text","preferredDefinition":"Description; a statement that represents something in words.:Text; the words of something written.","longName":"C25365:C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Description","conceptCode":"C25365","definition":"A written or verbal account, representation, statement, or explanation of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3D4E-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F2F1EFD-7551-6DE0-E053-F662850AB3C7","latestVersionIndicator":"Yes","beginDate":"2017-05-10","endDate":null,"createdBy":"RICHARDS","dateCreated":"2017-05-10","modifiedBy":"RICHARDS","dateModified":"2017-05-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3896529","version":"1","longName":"Consortia 2012 Studies","context":"DCP","ClassificationSchemeItems":[{"publicId":"5889179","version":"1","longName":"NWU2016-08-02","context":"DCP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"γ-OHPdG Level","type":"Preferred Question Text","description":"γ-OHPdG Level","url":null,"context":"DCP"}],"origin":"DCP:Division of Cancer Prevention","workflowStatus":"RELEASED","registrationStatus":"Application","id":"602D7C74-FEE3-0F7E-E053-F662850A0D31","latestVersionIndicator":"Yes","beginDate":"2017-12-12","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-12-12","modifiedBy":"ZHANGWE","dateModified":"2020-05-11","changeDescription":"12/12/2017 wz created for DCP SVAR.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}